Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL

by Zacks Equity Research

Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.

Seagen (SGEN) Posts Positive Data from New Study on Tukysa

by Zacks Equity Research

Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.

Seagen's (SGEN) Stock Up on CEO's Resignation Announcement

by Zacks Equity Research

Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.

Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.

Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 24.49% and 4.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seagen (SGEN) Gets Nod From EU for Bladder Cancer Drug, Padcev

by Zacks Equity Research

The European Commission approves Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.

Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study

by Zacks Equity Research

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.

Company News for Apr 12, 2022

by Zacks Equity Research

Companies In The News Are: TWTR, SGEN, T, LUV

Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets

by Zacks Equity Research

Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

by Zacks Equity Research

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

Why Is Seattle Genetics (SGEN) Up 12.7% Since Last Earnings Report?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

by Zacks Equity Research

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

by Zacks Equity Research

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

Seagen (SGEN) Q4 Earnings Miss, Revenues Top Mark, Stock Down

by Zacks Equity Research

Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -20.25% and 6.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Seattle Genetics (SGEN) Q4 Earnings Expected to Decline

by Zacks Equity Research

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seagen (SGEN) Gets Positive CHMP Opinion for Bladder Cancer Drug

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.

Seagen (SGEN) Q3 Loss Widens, Revenues Beat, 2021 Guidance Up

by Zacks Equity Research

Seagen's (SGEN) earnings miss estimates in the third quarter of 2021 while revenues beat the same. The company increases its financial guidance for 2021.

Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -187.50% and 9.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Seagen (SGEN) Might Surprise This Earnings Season

by Zacks Equity Research

Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Earnings Preview: Seattle Genetics (SGEN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry

by Zacks Equity Research

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study

by Zacks Equity Research

Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.

Ekta Bagri headshot

Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA

by Ekta Bagri

Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.